Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-RSV nanobody ALX-0171

A trivalent nanobody composed of three monovalent Nb017 moieties linked with glycine-serine (GS) linkers, directed against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with potential activity against RSV infections. Upon administration via nebulization and inhalation, the anti-RSV nanobody ALX-0171 targets and binds to RSV F protein, neutralizing the virus, and preventing viral entry into host cells. RSV F protein is a small envelope glycoprotein required for cytopathic syncytia formation that results from cell-to-cell fusion.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-RSV F nanobody ALX-0171
anti-RSV protein F nanobody ALX-0171
RSV-specific nanobody ALX-0171
Code name:ALX 0171
ALX-0171
ALX0171
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search